Further validation of GCK's efficacy and safety in higher-order models (such as animal studies and clinical trials) could potentially pioneer new technical pathways for urgently needed AD drug development in clinical practice, thereby advancing precision prevention and comprehensive treatment strategies for AD. This evidence concerns the gene GCK and Alzheimer disease.